Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report report published on Tuesday morning, Benzinga reports.

Separately, StockNews.com upgraded Aclaris Therapeutics from a sell rating to a hold rating in a research note on Thursday, July 25th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $23.00.

Aclaris Therapeutics Trading Down 5.0 %

NASDAQ:ACRS opened at $1.15 on Tuesday. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $6.98. The company has a market cap of $81.95 million, a price-to-earnings ratio of -1.06 and a beta of 0.21. The stock has a fifty day simple moving average of $1.23 and a 200-day simple moving average of $1.21.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. The business had revenue of $2.77 million during the quarter, compared to the consensus estimate of $1.74 million. As a group, equities research analysts predict that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at Aclaris Therapeutics

In related news, major shareholder Braden Michael Leonard bought 130,317 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were bought at an average price of $1.30 per share, for a total transaction of $169,412.10. Following the completion of the purchase, the insider now directly owns 13,578,286 shares of the company’s stock, valued at $17,651,771.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have purchased 930,502 shares of company stock worth $1,119,232 over the last quarter. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Aclaris Therapeutics during the first quarter worth about $39,000. SG Americas Securities LLC grew its stake in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 61,602 shares during the last quarter. Deuterium Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics during the first quarter worth about $99,000. Finally, Marquette Asset Management LLC purchased a new stake in shares of Aclaris Therapeutics during the first quarter worth about $104,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.